Dose Insider / Analyses / Muscle loss on GLP-1 drugs

Muscle Loss on Zepbound and WegovyHow Much of the Weight Lost Is Fat, and How Much Is Muscle

Updated November 20, 2026 · 23 min read · Body scan substudies, 2025 joint advisory

In body scans from the main Zepbound trial, about three quarters of the weight people lost was fat and one quarter was lean tissue.

74%of the weight lost in the body scans was fat
What the lost weight was made ofBody scans in the trials, share of the weight lostZepbound: fat74%Zepbound: lean tissue26%Wegovy: lean tissue38%What the lost weight wasmade ofBody scans in the trials, share of the weight lostZepbound: fat74%Zepbound: lean tissue26%Wegovy: lean tissue38%

Lean tissue includes muscle but also water and organs; the scans cannot separate them.

On this page

People who lost weight on placebo showed the same split. Lean tissue is not all muscle: about half of it is, so muscle made up roughly an eighth of the loss.

This page splits your own weight loss by those averages. Then it goes through what the scans measured, whether the drug or the weight loss is responsible, whether age, sex or dose changes the split, what MRI scans of the muscle show, how Wegovy compares, and what the 2025 advisory from four medical societies asks people on these drugs to do.

How much of my weight loss is fat, and how much is muscle?

Enter your weight before treatment and your weight now. The calculator divides the difference by the average split measured in the trial you choose.

Your loss, splitBody scans
Unit
Use the split measured in
Fat—
Lean tissue—

Log your weight in the app and see each month's change.

Open the app

Trial averages: 26% lean tissue in the Zepbound scans and 38% in the Wegovy scans. One person's split can differ. Lean tissue is muscle plus other tissue that is not fat. "About half muscle" is the estimate used in the 2025 advisory.

The calculator opens with someone who went from 231 lb to 185 lb. On the Zepbound trial's average, 34 lb of those 46 lb was fat and 12 lb was lean tissue, of which about 6 lb was muscle.

Two words need care. Lean tissue, or lean mass, is what a body scan reports as everything that is neither fat nor bone mineral. A joint advisory published in 2025 by four medical societies describes it as "muscle and other nonfat tissues" and gives a rule of thumb: "muscle mass is about half of lean body mass".3 The rest is other tissue that is not fat, organs among them. So a figure for lean tissue lost is about twice the figure for muscle lost.

Weight lostFat, Zepbound split lbLean tissue lbOf which muscleLean tissue, Wegovy split lb
20 lb155about 3 lb8
40 lb3010about 5 lb15
60 lb4416about 8 lb23
80 lb5921about 10 lb30

Our arithmetic: 74% fat and 26% lean tissue for Zepbound, 38% lean tissue for Wegovy, muscle taken as half of lean tissue.

What did the body scans in the trials measure?

Both big trials had a side study in which some participants were scanned at the start and at the end. The method is called DXA. It passes a weak X-ray beam over the whole body and sorts every part of it into fat, bone mineral and lean tissue.

In the Zepbound trial, 160 people were scanned at the start and at week 72: 124 on tirzepatide, at any of the three doses, and 36 on placebo. Of these, 73% were women, and the average starting weight was 102.5 kg (226 lb).1 In the Wegovy trial, 140 people were scanned at the start and at week 68: 95 on semaglutide and 45 on placebo.2

What changed in the scansDXA
Group

Each bar is the average fall as a percent of the starting amount. Zepbound and its placebo at week 72, Wegovy at week 68. Visceral fat is the fat around the organs in the abdomen.

Change from the startZepbound, week 72Placebo, week 72Wegovy, week 68
Body weight−21.3%−5.3%−15.0%
Fat mass−33.9%−8.2%−19.3%
Visceral fat−40.1%−7.3%−27.4%
Lean mass−10.9%−2.6%−9.7%
Fat mass, in kilograms−15.9 kg−3.6 kg—
Lean mass, in kilograms−5.6 kg−1.2 kg—
Waist−18.1 cm−3.4 cm—

Look and colleagues 2025 for Zepbound and placebo. Wilding and colleagues 2021 for Wegovy.

On Zepbound, people lost a third of their fat and about a ninth of their lean tissue. The fat around the organs, the kind linked to heart and metabolic disease, fell the most, by 40%. In kilograms, the average was 15.9 kg of fat and 5.6 kg of lean tissue, which is where the split of 74% and 26% comes from.1

Because fat fell three times as fast as lean tissue, the body that was left had a higher share of lean tissue than the body at the start. The Wegovy study reported this directly. Lean tissue fell by 9.7% in absolute terms, and yet its share of total body weight rose by 3 percentage points, from 53.9%, while the share of fat fell by 3.5 points.2 People ended up with less muscle and a more muscular body composition, both at once.

The Zepbound label summarises the same finding in a line: tirzepatide "lowers body weight with greater fat mass loss than lean mass loss".5

The average participant, in pounds

Percentages hide the actual amounts. Here are the averages from the scan studies converted to pounds, with muscle taken as half of lean tissue.

Average lossZepbound scansPlaceboWegovy scans
Fat35 lb (15.9 kg)8 lb (3.6 kg)18 lb (8.3 kg)
Lean tissue12 lb (5.6 kg)3 lb (1.2 kg)12 lb (5.3 kg)
Of which muscle, about halfabout 6 lbabout 1 lbabout 6 lb

Zepbound and placebo from the scan study. Wegovy as given in the 2025 advisory. Pounds are our conversion.

The lean tissue row is almost the same for the two drugs, 5.6 kg and 5.3 kg. The fat row is where they differ: nearly twice as much fat came off in the Zepbound study. That is the whole reason the Zepbound percentage for lean tissue looks lower. The amount of lean tissue lost was alike.

The waist figure shows where much of the fat went from. People on Zepbound lost 18.1 cm, about 7 inches, from their waist, against 3.4 cm on placebo, and their visceral fat fell by 40.1%. In the Wegovy study visceral fat fell by 27.4%.

Is the muscle loss caused by the drug or by the weight loss?

By the weight loss. The placebo group answers this. People on placebo injections lost much less weight, 5.3% against 21.3%, but what they lost had the same make-up: 75% fat and 25% lean tissue, against 74% and 26% on Zepbound.1 The drug changed how much weight came off. It did not change what the lost weight was made of.

Share of the weight lost that was lean tissue
On Zepbound, 21.3% weight loss26%
On placebo, 5.3% weight loss25%

The authors of the scan study put the reason plainly. A heavier body needs more muscle to carry it, so "some lean mass is gained with substantial weight gain due to the increased physiomechanical burden on skeletal muscle". The reverse follows: "some degree of lean mass will be lost with substantial weight reduction". Their conclusion is that tirzepatide "does not induce disproportionate lean mass loss compared with other established obesity treatment modalities".1

The joint advisory says the same about the class as a whole. The losses of fat, lean tissue and muscle "correlate with the degree of body weight reduction and are similar to those documented with other obesity therapies that achieve large weight reductions, such as bariatric surgery and very low-calorie restricted diets".3

That does not make the loss harmless. It moves the question. The amount of lean tissue lost follows the amount of weight lost, and these drugs take off a lot of weight. Someone who loses 60 lb gives up about 16 lb of lean tissue on the trial average, however the 60 lb was lost.

Does age, sex or dose change the split?

Very little, in the Zepbound scans. The study divided the people on tirzepatide by age, by sex, by how much weight they had lost and by dose, and worked out the share of fat in the weight lost for each group.1

The split, group by groupSURMOUNT-1
Divide people by

People on tirzepatide in the scan study, 124 in all, so each group is small. The bar is the share of the weight lost that was fat. The rest was lean tissue.

Group, on ZepboundFatLean tissue
Under 5074%26%
50 to 6475%25%
65 and over76%24%
Women75%25%
Men73%27%
Lost 15.3 kg or less70%30%
Lost 15.3 to 25.9 kg73%27%
Lost more than 25.9 kg76%24%
On 5 mg75%25%
On 10 mg72%28%
On 15 mg75%25%

Look and colleagues, Diabetes, Obesity and Metabolism 2025.

Every group falls between 70% and 76% fat. The result for age is the one people worry about most, and it goes against the worry: among people aged 65 and over, 76% of the loss was fat, slightly more than in those under 50. The authors write that tirzepatide "was not associated with a proportionally greater loss of lean tissue in older adults".

Men and women lost the same share. The study tested the difference between the sexes for each measure and found none that was statistically meaningful.

The weight-lost row has a detail worth noticing. People who lost the least had the highest share of lean tissue in their loss, 30%, and those who lost the most had the lowest, 24%. Losing more weight did not mean losing a larger share of it as lean tissue. It did mean losing more lean tissue in kilograms, because 24% of a large loss is more than 30% of a small one.

The dose made no visible difference either. Fat was 75%, 72% and 75% of the loss on 5, 10 and 15 mg. A higher dose took off more weight in total and did not shift what the weight was made of.

One figure in the paper falls outside the range, and it belongs to placebo: among people aged 65 and over who received placebo, only 63% of the small amount of weight they lost was fat. The authors list it as an exception and warn that the subgroups were small, the placebo ones especially.

A caution comes from the authors themselves. These groups are small, some with fewer than a dozen people on placebo, and they advise against drawing conclusions from small differences between them. The safe reading is the broad one: the split was about three to one in every group that was looked at.

Does losing weight faster cost more muscle?

The joint advisory lists speed among the things that matter: lean mass reduction "is also affected by the degree of calorie restriction, overall rapidity of weight reduction, and presence or absence of strength training exercises".3 So in general, a harder and faster cut takes more lean tissue with it.

The Zepbound scans do not show that effect within the trial. People who lost the most weight did not lose a larger share of it as lean tissue. Their share was 24%, against 30% in those who lost the least.1 The trial was not built to test speed, and everyone in it followed the same slow step-up of the dose over 20 weeks, so this does not overturn the general rule. It does mean that a large loss on this drug, reached at the trial's pace, was not paid for with a worse split.

The practical reading is about the early months. The fastest loss comes in the first six months of treatment, and that is the period in which the advisory's two protections, strength training and enough protein, have the most to protect.

What do MRI scans of the muscle itself show?

A DXA scan cannot tell muscle from the other lean tissue. MRI can. In one of the diabetes trials of tirzepatide, 246 people, 190 of them on tirzepatide, had an MRI of the thigh at the start and after 52 weeks, and the researchers measured two things: the volume of the muscle and the amount of fat lodged inside it.4

Thigh muscle after 52 weeks on tirzepatideChangeAgainst what the weight loss alone would predict
Muscle volume−0.64 litresno clear difference (−0.04 litres)
Fat inside the muscle−0.36 percentage pointsa larger fall than predicted (by 0.42 points)

Sattar and colleagues, Lancet Diabetes & Endocrinology 2025, SURPASS-3 MRI substudy, pooled doses.

The muscle got smaller, as the DXA figures would suggest. The useful part is the comparison. The researchers used repeat MRI scans from 2,942 people in the UK Biobank to work out how much muscle volume normally changes when body weight changes by a given amount. The loss on tirzepatide matched that expectation: the difference was 0.04 litres and not statistically clear. The muscle shrank by about as much as it does in anyone who loses that much weight.

The fat inside the muscle fell by more than expected. The authors treat a fall in the fat inside muscle as a change in the right direction, and their summary is cautious: the treatment was associated with "potentially favourable changes in muscle fat infiltration and reductions in muscle volume broadly in accordance with the general association between changes in muscle volume and bodyweight".4

One result cut the other way. On the 15 mg dose, a measure of muscle volume adjusted for body size fell slightly more than the population data predicted. And the participants had type 2 diabetes and were treated for a year, so the study does not describe everyone on Zepbound. Within those limits it is the most direct look at muscle available, and it shows smaller muscles with less fat in them.

Does losing lean tissue make people weaker?

The scan studies did not test strength, so they cannot answer this directly. What the Zepbound trial did collect is a standard health questionnaire, the SF-36, which includes scores for physical function. The authors of the scan study report that tirzepatide "significantly improved patient-reported physical function" compared with placebo, in spite of the fall in lean mass.1

Their explanation is that the fat lost matters more for moving around than the lean tissue lost. A person who weighs 46 lb less has 46 lb less to lift on every stair. They point to research on weight-loss surgery that found the same thing: physical function improved although lean mass fell, and the fall in body weight was the strongest predictor of the improvement.

The joint advisory notes that this gap is being worked on: research "is underway to examine how GLP-1 therapy affects muscle quality and physical function in younger populations".3

A questionnaire is a person's own impression, and it is not a grip-strength test. It also describes the average participant in a trial of adults with obesity. The authors mark out one group for whom the average may not hold: a fall in lean mass "may be undesirable for older adults with or at risk of developing sarcopenic obesity", the combination of low muscle and high fat.

Is it different on Wegovy?

The published figure for Wegovy is higher. In the scan study of its main trial, lean tissue made up about 38% of the weight lost, against 26% in the Zepbound study. The joint advisory gives the Wegovy figures in kilograms: of an average 13.6 kg lost, 8.3 kg was fat and 5.3 kg was lean tissue. It adds that, with muscle at about half of lean tissue, this "corresponds to ~20% of total weight reduction being muscle loss".3

Zepbound scan studyWegovy scan study
People on the drug who were scanned12495
Weight lost21.3%15.0%
Fat mass−33.9%−19.3%
Lean mass−10.9%−9.7%
Lean tissue as a share of the loss26%38%
Muscle as a share of the loss, at half of leanabout 13%about 19%

The two numbers come from two separate studies and should not be read as a contest. The studies used different scanners at different sites and enrolled different people: the Wegovy substudy took only participants with a BMI of 40 or under. Neither drug's study was designed to be compared with the other, and no trial among the sources used here scanned people on both drugs side by side.

The lean mass row shows how close the two are in one respect. People lost 10.9% of their lean tissue on Zepbound and 9.7% on Wegovy. The share looks different mainly because Zepbound took off much more fat alongside it.

The Wegovy study expressed the balance as a ratio. At the start, participants had 1.34 kg of lean tissue for every kilogram of fat. By week 68 the ratio had risen by 0.23, which means more lean tissue per kilogram of fat than before.

The Wegovy study also found that the balance improved with larger losses. The ratio of lean to fat tissue rose by 0.41 in people who lost 15% or more of their weight and by 0.03 in those who lost less.2

Who should pay the most attention?

The joint advisory names the people for whom low protein intake and muscle loss are a greater concern: "those with older age, perimenopausal or menopausal status, lower testosterone, sedentary behavior, or lack of resistance/strength training".3

It also cites modelling that separates men and women. In the absence of structured strength training, muscle is estimated at 10% to 15% of the total weight lost in women and 20% to 25% in men.

Muscle as a share of the weight lost, without strength training
Women · modelling cited in the advisory10% to 15%
Men · modelling cited in the advisory20% to 25%

Bone is part of the same picture. The advisory notes that weight loss which is large, 14% or more, and fast, over three to four months, "is associated with significant bone loss", while slower loss may protect bone better. It cites a randomized trial in which a year of a GLP-1 drug combined with exercise training kept bone mineral density steady, while the drug alone lowered it.3

For someone in one of those groups, the arithmetic at the top of the page is a reason to act early, during the months when the weight is coming off fastest, and to raise the subject with the prescriber.

What if I am over 65?

The share of lean tissue in the loss was no higher for older people in the Zepbound scans: 24% in those aged 65 and over, 25% in those aged 50 to 64 and 26% in those under 50.1 The label makes a matching general statement about age. In its two main trials, 226 people on Zepbound, 9%, were 65 or older, and "no overall differences in safety or effectiveness" were seen between them and younger adults.5

The same share can still matter more for someone whose muscle is already low. This is why the authors of the scan study, having found no difference in the split, still write that a fall in lean mass may be undesirable for older adults at risk of sarcopenic obesity. They add that weight reduction remains recommended even then, "along with lifestyle interventions focusing on minimizing lean mass loss".

The numbers for people over 65 rest on few participants, and only 13 people in the main trials were 75 or older. For that age group the trial evidence is thin, and the case for measuring and protecting muscle from the start is strongest.

What protects muscle during treatment?

The advisory names two things, exercise and protein, and is more definite about the first.

Strength training

Its recommendation is specific. The drugs "should be prescribed together with a structured exercise program, aiming for regular strength training at least three times weekly plus at least 150 min of moderate-intensity aerobic exercise weekly to preserve muscle and bone mass".3

The exercise target in the 2025 advisory
Strength trainingat least 3 times a week
Moderate aerobic exerciseat least 150 minutes a week

The evidence behind it is about weight loss in general. Programmes of resistance training, or resistance mixed with aerobic exercise, "are well established to help preserve lean mass during weight reduction", the advisory says, while "aerobic activity alone has a smaller effect". Walking is good for many things. For holding on to muscle, lifting is the part that counts. The advisory adds that plans "should be customized to match the individual's fitness level and physical capacity".

Among people actually taking these drugs, the advisory cites retrospective studies that support structured programmes, "for example, 360 min/week with an emphasis on strength exercises to preserve fat-free mass". That is six hours a week, well above its own minimum target.

One trial has tested exercise together with a drug of this family. In Copenhagen, adults who combined a supervised exercise programme with liraglutide for a year were compared with adults who only took the drug. A year after all treatment ended, the combined group weighed 5.1 kg less and had a body-fat percentage 2.3 points lower than the drug-only group.6

Protein

Appetite falls on these drugs, and total food intake falls with it. The advisory's concern is that protein falls too: "Low protein consumption due to reduced appetite may also contribute to muscle loss".3 It lists the reference points.

Protein reference pointAmount
Recommended daily allowance for adults in general0.8 g per kg of body weight
Proposed during active weight loss1.2 to 1.6 g per kg
Per kg of lean tissue, if body composition is known1.5 g
A simple absolute target80 to 120 g a day
Floor: intake should not fall below0.4 to 0.5 g per kg

Mozaffarian and colleagues, Obesity 2025.

The advisory is open about what is not settled. For people with obesity, "it is unclear whether these goals should be based on actual body weight", an adjusted weight or lean mass, because using actual weight "can significantly overestimate protein requirements". That is why it offers the flat range of 80 to 120 grams a day as the practical option. It also gives one eating tip with a reason attached: protein-rich foods "can be consumed first in a meal to increase the likelihood of sufficient consumption", before fullness sets in.

Applying the per-kilogram figures to actual body weight shows the problem the advisory describes.

Body weightGeneral allowance, 0.8 g per kg gWeight-loss range, 1.2 to 1.6 g per kg g
70 kg (154 lb)5684 to 112
85 kg (187 lb)68102 to 136
100 kg (220 lb)80120 to 160
120 kg (265 lb)96144 to 192

Our multiplication of the advisory's per-kilogram figures by actual body weight.

At 120 kg the per-kilogram range runs to 192 grams a day, far past the flat target of 80 to 120 grams, and that is a lot of protein for someone whose appetite is reduced. The advisory also sets a ceiling: prolonged intake at or above 2 grams per kilogram a day "should be avoided due to potential adverse health effects".

On food, the advisory encourages plant sources such as beans, peas and lentils, along with dairy, seafood, eggs and lean poultry, and suggests keeping red and processed meat moderate. For small appetites it names foods that pack protein into a small volume: fish, eggs, Greek yogurt, cottage cheese, nuts and seeds. It notes that some people meet their target with high-protein shakes or bars.3

None of the sources used here is a trial in which people on Zepbound or Wegovy were assigned to more or less protein and then scanned. The protein advice rests on studies of weight loss by diet, carried over to these drugs.

How can muscle be tracked, and not only weight?

A bathroom scale shows the total and says nothing about the split. The advisory lists three ways to measure body composition, with their trade-offs.3

MethodWhat the advisory says about it
Bioelectrical impedance (BIA)pragmatic, low cost, easy to repeat at a clinic visit
Air displacementan option for people with pacemakers or other electronic implants, who cannot use BIA
DXA scan"considered a gold standard", but more costly and done less often

The advisory suggests repeated impedance measurements in particular "when weight reduction trajectories are high and muscle loss is more likely". In the Zepbound trial the pace was fastest in the first six months. A single reading tells little. The change between two readings on the same device is the useful number.

The advisory points out a gap in all three: they "monitor muscle mass but not muscle health, quality, or function". For function it mentions simple timed tests, such as standing up from a chair, climbing stairs, and the timed up-and-go, which it calls helpful in older adults though less able to pick up change in younger people. Handgrip strength is easy to measure and, in its words, less sensitive to change.

Without any device, the trial averages give a yardstick. If the scale shows 40 lb lost, about 10 lb of lean tissue lost would be the average result. A measured loss far above that share is worth showing to the prescriber.

What should I raise with my prescriber?

The advisory was written for clinicians, and its points translate into questions a patient can ask.

  1. Am I in a higher-risk group? Older age, menopause, low testosterone and little physical activity are the ones it names.
  2. Should my body composition be measured now? A starting reading makes later ones meaningful.
  3. What strength programme fits me? The advisory mentions referral to an exercise physiologist or physical therapist where appropriate.
  4. What is my protein target, and on what weight is it based? The flat range is 80 to 120 grams a day.
  5. Does my bone density need checking? The advisory lists osteopenia and osteoporosis among the conditions to ask about before treatment.

What can these studies not tell you?

The scan studies were small. 124 people on Zepbound and 95 on Wegovy were scanned, out of trials of about 2,500 and 1,900. The subgroup figures rest on a few dozen people each.

DXA measures lean tissue, not muscle. The muscle figures on this page apply the advisory's rule of thumb that muscle is about half of lean tissue.

Nobody measured strength. The function result comes from a questionnaire. Grip strength, walking speed and falls were not among the results reported in these sources.

The people were mostly middle-aged women with obesity. In the Zepbound scan study 73% were women. Older adults were a small group.

Nobody was scanned after stopping. These sources do not show what regained weight is made of on these drugs.

The drug makers ran the trials. The Zepbound and Mounjaro studies were run by Eli Lilly and the Wegovy study by Novo Nordisk. The advisory was written by four professional societies.

Short answers to common questions

Does Zepbound cause muscle loss?

Weight loss does, and Zepbound causes weight loss. In the trial scans 26% of the weight lost was lean tissue, the same share as in people who lost weight on placebo, and about half of lean tissue is muscle.

How much muscle will I lose if I lose 50 lb?

On the Zepbound trial's average, about 13 lb of lean tissue, of which about 6 to 7 lb is muscle, and 37 lb of fat.

Is a quarter of the loss as lean tissue a lot?

It is the usual figure for large weight losses by any method. The authors of the Zepbound scan study describe it as three times as much fat lost as lean tissue, "consistent with other therapies".

Is muscle loss worse for people over 65?

Not as a share, in the Zepbound scans: 76% of the loss was fat in people 65 and over, against 74% in people under 50. Older adults start with less muscle, though, and the authors and the advisory both single them out as the group to protect.

Does Zepbound or Wegovy preserve more muscle?

That has not been tested head to head. Separate studies found 26% of the loss as lean tissue on Zepbound and 38% on Wegovy, with different scanners and different participants. People lost a similar share of their lean tissue on each: 10.9% and 9.7%.

How much protein should I eat?

The 2025 advisory offers 80 to 120 grams a day as a practical target and cites 1.2 to 1.6 grams per kilogram as a range proposed for active weight loss. It notes that the right basis for people with obesity is not settled.

Is walking enough?

For muscle, the advisory says aerobic activity alone has a smaller effect than resistance training. Its target is strength training at least three times a week plus 150 minutes of moderate aerobic exercise.

Do I need a DXA scan?

The advisory calls it a gold standard but costly, and points to bioelectrical impedance as the practical tool for repeated checks. Whether to measure at all is something to decide with your prescriber.

Will I lose muscle if I do no strength training?

Modelling cited in the advisory puts muscle at 10% to 15% of the weight lost in women and 20% to 25% in men when there is no structured strength training. The trials did not assign people to train or not, so there is no measured figure for Zepbound.

Does the muscle come back if the weight comes back?

None of the sources here scanned people after they stopped the drug, so the make-up of regained weight on these drugs has not been measured in them.

How the calculator works

The calculator takes the difference between your two weights and multiplies it by the share of lean tissue measured in the scan study you select: 26% for the Zepbound trial and 38% for the Wegovy trial, the second figure as given in the 2025 advisory. The rest is counted as fat. Muscle is shown as half of the lean tissue, following the advisory's statement that muscle mass is about half of lean body mass.

The scan chart shows the published percent changes from the two substudies. The group chart shows the share of fat in the weight lost for each subgroup of people on tirzepatide. All of these are averages over a hundred or so people, and none of them is a measurement of you.

Sources

  1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. doi:10.1111/dom.16275
  2. Wilding J, Batterham R, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc 2021;5(Suppl 1):A16-A17. PMC8089287
  3. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
  4. Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 2025;13:482-493. doi:10.1016/S2213-8587(25)00027-0
  5. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 12.2. accessdata.fda.gov
  6. Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 2024;69:102475. doi:10.1016/j.eclinm.2024.102475

Related analyses

Log your weight and see each month's change in the app.

Open Dose Insider